Follow
C.E.M. Hollak
C.E.M. Hollak
Amsterdam University Medical Centers
No verified email
Title
Cited by
Cited by
Year
Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease.
CE Hollak, S van Weely, MH Van Oers, JM Aerts
The Journal of clinical investigation 93 (3), 1288-1292, 1994
11021994
Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis
T Cox, R Lachmann, C Hollak, J Aerts, S Van Weely, M Hrebícek, F Platt, ...
The Lancet 355 (9214), 1481-1485, 2000
9472000
Elevated globotriaosylsphingosine is a hallmark of Fabry disease
JM Aerts, JE Groener, S Kuiper, WE Donker-Koopman, A Strijland, ...
Proceedings of the National Academy of Sciences 105 (8), 2812-2817, 2008
7842008
Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention
RG Boot, M Verhoek, M De Fost, CEM Hollak, M Maas, B Bleijlevens, ...
Blood 103 (1), 33-39, 2004
3972004
Characterization of classical and nonclassical Fabry disease: a multicenter study
M Arends, C Wanner, D Hughes, A Mehta, D Oder, OT Watkinson, ...
Journal of the American Society of Nephrology 28 (5), 1631-1641, 2017
3552017
Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document
M Biegstraaten, R Arngrímsson, F Barbey, L Boks, F Cecchi, PB Deegan, ...
Orphanet journal of rare diseases 10, 1-10, 2015
3552015
Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta
GE Linthorst, CEM Hollak, WE Donker-Koopman, A Strijland, JMFG Aerts
Kidney international 66 (4), 1589-1595, 2004
3172004
Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response
N Dekker, L van Dussen, CEM Hollak, H Overkleeft, S Scheij, ...
Blood, The Journal of the American Society of Hematology 118 (16), e118-e127, 2011
2972011
The role of the iminosugar N‐butyldeoxynojirimycin (miglustat) in the management of type I (non‐neuronopathic) Gaucher disease: A position statement
TM Cox, J Aerts, G Andria, M Beck, N Belmatoug, B Bembi, R Chertkoff, ...
Journal of inherited metabolic disease 26 (6), 513-526, 2003
2902003
Elevated plasma chitotriosidase activity in various lysosomal storage disorders
Y Guo, W He, AM Boer, RA Wevers, AM De Bruijn, JEM Groener, ...
Journal of inherited metabolic disease 18 (6), 717-722, 1995
2901995
Sustained therapeutic effects of oral miglustat (Zavesca, N‐butyldeoxynojirimycin, OGT 918) in type I Gaucher disease
D Elstein, C Hollak, J Aerts, S Van Weely, M Maas, TM Cox, ...
Journal of inherited metabolic disease 27 (6), 757-766, 2004
2852004
Ultrasensitive in situ visualization of active glucocerebrosidase molecules
MD Witte, WW Kallemeijn, J Aten, KY Li, A Strijland, WE Donker-Koopman, ...
Nature chemical biology 6 (12), 907-913, 2010
2772010
Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg
AC Vedder, GE Linthorst, G Houge, JEM Groener, EE Ormel, BJ Bouma, ...
PloS one 2 (7), e598, 2007
2712007
Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease
SM Rombach, N Dekker, MG Bouwman, GE Linthorst, AH Zwinderman, ...
Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1802 (9), 741-748, 2010
2702010
The Dutch Fabry cohort: Diversity of clinical manifestations and Gb3 levels
AC Vedder, GE Linthorst, MJ Van Breemen, JEM Groener, FJ Bemelman, ...
Journal of Inherited Metabolic Disease: Official Journal of the Society for …, 2007
2362007
Increased incidence of cancer in adult Gaucher disease in Western Europe
M de Fost, S Vom Dahl, GJ Weverling, N Brill, S Brett, D Häussinger, ...
Blood Cells, Molecules, and Diseases 36 (1), 53-58, 2006
2362006
A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance
L Van der Tol, BE Smid, B Poorthuis, M Biegstraaten, RHL Deprez, ...
Journal of medical genetics 51 (1), 1-9, 2014
2342014
Gaucher disease type 1: revised recommendations on evaluations and monitoring for adult patients
NJ Weinreb, MC Aggio, HC Andersson, G Andria, J Charrow, JTR Clarke, ...
Seminars in hematology 41, 15-22, 2004
2152004
4 Plasma and metabolic abnormalities in Gaucher's disease
JMFG Aerts, CEM Hollak
Baillière's clinical haematology 10 (4), 691-709, 1997
2081997
Quantification of bone involvement in Gaucher disease: MR imaging bone marrow burden score as an alternative to Dixon quantitative chemical shift MR imaging—initial experience
M Maas, C van Kuijk, J Stoker, CEM Hollak, EM Akkerman, JFMG Aerts, ...
Radiology 229 (2), 554-561, 2003
2052003
The system can't perform the operation now. Try again later.
Articles 1–20